[Erster Bericht über eine kontrollierte klinische Untersuchung zur Prednisolon-Behandlung der thorakalen Sarkoidose].
117 patients with histologically confirmed mediastino-pulmonary sarcoidosis stage I and II without extrapulmonary manifestations were included in a controlled therapeutic trial. 92 patients remained for analysis. Among these 54 were treated for 6 or 12 months with prednisolone and isoniacid; 38 were not treated. 6 and 12 months after beginning the observation, improvement was more frequent in the treated group. After 3 years and 5 years (45 patients only) however differences were no more evident: improvement was observed in about 80 per cent, complete remission in about 65 per cent in treated and untreated patients. In both groups, patients presenting dissemination in the lungs had worse results than those with hilo-mediastinal adenopathy associated or not with pulmonary dissemination. Prednisolone seems to have effects in the early phase of sarcoidosis but is apparently not so effective in respect to the general development of the illness and in preventing pulmonary fibrosis. Therefore strict indication for therapy with corticosteroids of sarcoidosis exist when progressive pulmonary dissemination and/or reduction of pulmonary function is evident.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D005859:Germany, East; D006801:Humans; D008134:Long-Term Care; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008477:Mediastinal Diseases / Q000188:drug therapy*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D011658:Pulmonary Fibrosis / Q000517:prevention & control; D012507:Sarcoidosis / Q000188:drug therapy*
D011239:Prednisolone